孕妇接种BNT162b2 mRNA新冠疫苗的短期结局
这项观察性病例对照研究比较了390名孕期接种两剂BNT162b2疫苗的孕妇与260名年龄匹配的非妊娠接种女性,发现孕妇不良反应谱与非妊娠女性相似,未提示安全性担忧;孕妇SARS-CoV-2 IgG水平显著低于非妊娠女性,但所有样本抗体均为阳性。
要点
- 孕妇接种BNT162b2疫苗后不良反应谱与非妊娠女性相似,未提示安全性担忧。
- 孕妇SARS-CoV-2 IgG水平显著低于非妊娠女性(信号截断比27.03 vs 34.35,P<0.001)。
- 57名分娩孕妇中无早产<37周、无胎死或新生儿死亡,产科并发症率低。
核心结论
- 孕妇在孕期任何阶段接种BNT162b2疫苗的不良反应谱及短期产科和新生儿结局未提示安全性担忧。
- 疫苗可在孕妇中有效产生体液免疫应答,但SARS-CoV-2 IgG水平低于非妊娠接种女性。
研究设计与样本
- 观察性病例对照研究,研究组为2021年1月至2月孕期接种两剂BNT162b2疫苗的孕妇,对照组为同时期接种的年龄匹配非妊娠女性。
- 539名完成两剂接种的孕妇中390名返回电子问卷纳入研究组,对照组为260名年龄匹配非妊娠接种女性。
- 接种后1-4周发送电子问卷收集人口学、用药、病史、SARS-CoV-2感染史、接种时间及每剂不良反应;研究组在预产期后发送第二份问卷了解妊娠和分娩结局。
- 所有招募女性在第二剂接种后接受SARS-CoV-2 IgG血清学检测,比较两组IgG水平。
主要发现
- 孕妇接种后皮疹、发热和严重疲劳发生率与非妊娠女性相当。
- 孕妇每剂接种后肌痛、关节痛和头痛显著更少见;第一剂后局部疼痛或肿胀、第二剂后腋窝淋巴结病显著更少见;第二剂后感觉异常显著更常见。
- 孕妇中不同孕期接种的不良反应率无显著差异,除外第一剂在第三孕期接种时局部疼痛/肿胀显著更少见,第二剂在第三孕期接种时子宫收缩显著更常见。
- 产科并发症率很低:子宫收缩第一剂后1.3%、第二剂后6.4%;阴道出血第一剂后0.3%、第二剂后1.5%;胎膜早破第一剂后0%、第二剂后0.8%。
- 两组所有血清样本SARS-CoV-2 IgG均为阳性,但孕妇血清SARS-CoV-2 IgG水平显著低于非妊娠女性(信号截断比27.03 vs 34.35,P<0.001)。
临床怎么用
- 孕期接种BNT162b2疫苗未提示短期安全性担忧,可作为孕期新冠疫苗接种咨询依据。
- 孕妇接种后抗体水平低于非妊娠女性,需关注其免疫保护程度。
局限性
- 研究为观察性设计,样本量有限,分娩结局仅基于57名完成第二份问卷的孕妇。
- 短期随访,未评估长期母婴结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the immunogenicity and reactogenicity of the Pfizer/BioNTech BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine among pregnant women compared with non-pregnant women, and to evaluate obstetric outcome following vaccination. METHODS: This was an observational case-control study of pregnant women who were vaccinated with a two-dose regimen of the BNT162b2 vaccine during gestation between January and February 2021 (study group) and age-matched non-pregnant women who received the vaccine during the same time period (control group). Participants received a digital questionnaire 1-4 weeks after the second dose and were asked to provide information regarding demographics, medication, medical history, history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, timing of COVID-19 vaccine doses and side effects after each vaccine dose. A second digital questionnaire, regarding current pregnancy and delivery outcomes, was sent to patients in the study group after the calculated due date. All recruited women were offered a serology blood test for SARS-CoV-2 immunoglobulin G (IgG) following the second vaccination dose and SARS-CoV-2 IgG levels were compared between the two groups. RESULTS: Of 539 pregnant women who were recruited after completion of the two-dose regimen of the vaccine, 390 returned the digital questionnaire and were included in the study group and compared to 260 age-matched non-pregnant vaccinated women. The rates of rash, fever and severe fatigue following vaccination among pregnant women were comparable to those in non-pregnant women. Myalgia, arthralgia and headache were significantly less common among pregnant women after each dose, local pain or swelling and axillary lymphadenopathy were significantly less common among pregnant women after the first and second doses, respectively, while paresthesia was significantly more common among the pregnant population after the second dose. Among pregnant women, there were no significant differences in the rates of side effects according to whether the vaccine was administered during the first, second or third trimester of pregnancy, except for local pain/swelling, which was significantly less common after the first dose when administered during the third trimester, and uterine contractions, which were significantly more common after the second dose when administered during the third trimester. The rates of obstetric complications, including uterine contractions (1.3% after the first dose and 6.4% after the second dose), vaginal bleeding (0.3% after the first dose and 1.5% after the second dose) and prelabor rupture of membranes (0% after the first dose and 0.8% after the second dose), were very low following vaccination. All serum samples in both groups were positive for SARS-CoV-2 IgG. However, pregnant women had significantly lower serum SARS-CoV-2 IgG levels compared to non-pregnant women (signal-to-cut-off ratio, 27.03 vs 34.35, respectively; P < 0.001). Among the 57 pregnant women who delivered during the study period and who completed the second questionnaire, median gestational age at delivery was 39.5 (interquartile range, 38.7-40.0) weeks, with no cases of preterm birth < 37 weeks, no cases of fetal or neonatal death and two (3.5%) cases of admission to the neonatal intensive care unit for respiratory support. CONCLUSIONS: The adverse-effect profile and short-term obstetric and neonatal outcomes among pregnant women who were vaccinated with the BNT162b2 vaccine at any stage of pregnancy do not indicate any safety concerns. The vaccine is effective in generating a humoral immune response in pregnant women, although SARS-CoV-2 IgG levels were lower than those observed in non-pregnant vaccinated women. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Bookstein Peretz S, Regev N, Novick L, et al. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. Ultrasound Obstet Gynecol. 2021. PMID: 34198360. doi:10.1002/uog.23729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。